Huang Huageng, Yu Le, Weng Huawei, Zhang Wei, Wang Zhao, Wang Lin, Huang He
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, P. R. China.
Department of Medical Oncology, Senior Ward and Phase I Clinical Trial Ward, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610000, P. R. China.
J Hematol Oncol. 2024 Dec 5;17(1):120. doi: 10.1186/s13045-024-01639-1.
Chimeric antigen receptor (CAR)-T cell therapy has emerged as one of the most rapidly evolving modalities of immunotherapy, with substantial success in the treatment of hematological malignancies and encouraging outcomes in solid tumors. Yet, the efficacy of CAR-T therapy is hindered by challenges such as suboptimal expansion and persistence, adverse events, a scarcity of ideal targets, high immunosuppression, and insufficient infiltration due to the intricate tumor microenvironment, all of which limit its application. The 2024 European Society for Medical Oncology (ESMO) Congress presented novel CAR-T cell therapies for hematologic and solid malignancies, focusing on strategies such as cytokine modulation, innovative targets, allogeneic development, mRNA vaccine synergy, in vivo delivery and conditional activation to surmount these challenges.
嵌合抗原受体（CAR）-T细胞疗法已成为免疫疗法中发展最为迅速的模式之一，在血液系统恶性肿瘤的治疗中取得了显著成功，在实体瘤治疗中也取得了令人鼓舞的成果。然而，CAR-T疗法的疗效受到诸多挑战的阻碍，如扩增和持久性欠佳、不良事件、理想靶点稀缺、高度免疫抑制以及由于复杂的肿瘤微环境导致的浸润不足等，所有这些都限制了其应用。2024年欧洲医学肿瘤学会（ESMO）大会展示了针对血液系统和实体恶性肿瘤的新型CAR-T细胞疗法，重点关注细胞因子调节、创新靶点、异基因开发、mRNA疫苗协同作用、体内递送和条件激活等策略，以克服这些挑战。
